LGT209 50 mg
DrugActive experimental drug
NCT Number: NCT01859455
This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1
Novartis Investigative Site, Fort Myers, Florida, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Healthy volunteers:
Statin patients:
Other protocol-defined inclusion/exclusion criteria may apply.
Active experimental drug
Active experimental drug
Placebo comparator
Stable doses of atorvastatin or simvastatin
Other names: Atorvastatin, Simvastatin
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: baseline and 12 weeks
Time frame: baseline and 12 weeks
Time frame: 2 weeks
Time frame: 2 weeks
Time frame: 12 weeks
Novartis Pharmaceuticals
Industry
A Randomized, Double-blind, Placebo-controlled, Single Dose, Parallel Group Study to Assess the Safety, Tolerability, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous LGT209 in Hypercholesterolemic Patients on Stable Doses of Atorvastatin or Simvastatin and in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02938949
Cardiovascular Diseases, Dyslipidemias
Richmond, Virginia, United States
View Trial DetailsNCT01979601
Dyslipidemias, Hypercholesterolemia
Miami Gardens, Florida, United States
View Trial DetailsNCT07737067
Arthrosclerosis, Dyslipidemias
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05694260
Dyslipidemias, Hypercholesterolemia
Los Angeles, California, United States
View Trial Details